Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more
Alnylam Pharmaceuticals Inc (ALNY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.207x
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) has a cash flow conversion efficiency ratio of 0.207x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($163.56 Million) by net assets ($789.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alnylam Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Alnylam Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alnylam Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Barclays PLC
PINK:BCLYF
|
N/A |
|
COINBASE GLB.CL.A -00001
F:1QZ
|
N/A |
|
DELL TECHS INC. C DL-01
XETRA:12DA
|
-0.447x |
|
COMPASS GROUP LS-1105
XETRA:XGR2
|
0.192x |
|
Nordea Bank Abp
PINK:NBNKF
|
0.022x |
|
Orsted A/S
PINK:DOGEF
|
0.129x |
|
Deutsche Post AG NA O.N.
LSE:0H3Q
|
0.147x |
|
Waste Connections Inc
NYSE:WCN
|
0.068x |
Annual Cash Flow Conversion Efficiency for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alnylam Pharmaceuticals Inc from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $789.18 Million | $524.08 Million | 0.664x | +636.00% |
| 2024-12-31 | $67.09 Million | $-8.31 Million | -0.124x | +73.75% |
| 2023-12-31 | $-220.64 Million | $104.16 Million | -0.472x | -113.80% |
| 2022-12-31 | $-158.22 Million | $-541.27 Million | 3.421x | +413.58% |
| 2021-12-31 | $588.20 Million | $-641.69 Million | -1.091x | -80.28% |
| 2020-12-31 | $1.02 Billion | $-614.96 Million | -0.605x | -212.68% |
| 2019-12-31 | $1.44 Billion | $-278.43 Million | -0.194x | +55.22% |
| 2018-12-31 | $1.30 Billion | $-562.62 Million | -0.432x | -99.41% |
| 2017-12-31 | $1.77 Billion | $-382.79 Million | -0.217x | +35.19% |
| 2016-12-31 | $920.22 Million | $-307.70 Million | -0.334x | -123.59% |
| 2015-12-31 | $1.26 Billion | $-189.14 Million | -0.150x | +15.47% |
| 2014-12-31 | $936.27 Million | $-165.64 Million | -0.177x | +30.34% |
| 2013-12-31 | $270.35 Million | $-68.66 Million | -0.254x | +70.55% |
| 2012-12-31 | $134.05 Million | $-115.61 Million | -0.862x | -16.88% |
| 2011-12-31 | $118.00 Million | $-87.07 Million | -0.738x | -38.44% |
| 2010-12-31 | $158.23 Million | $-84.34 Million | -0.533x | -31.48% |
| 2009-12-31 | $177.97 Million | $-72.14 Million | -0.405x | -225.12% |
| 2008-12-31 | $202.12 Million | $65.49 Million | 0.324x | -67.16% |
| 2007-12-31 | $199.17 Million | $196.52 Million | 0.987x | +905.92% |
| 2006-12-31 | $201.17 Million | $-24.63 Million | -0.122x | +54.12% |
| 2005-12-31 | $61.78 Million | $-16.48 Million | -0.267x | +37.09% |
| 2004-12-31 | $46.14 Million | $-19.57 Million | -0.424x | -188.30% |
| 2003-12-31 | $-26.71 Million | $-12.83 Million | 0.480x | +74.62% |
| 2002-12-31 | $-4.65 Million | $-1.28 Million | 0.275x | -- |